GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Liraglutide / Semaglutide

Company
Dasman Diabetes Institute
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
4 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

4 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Liraglutide / Semaglutide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05390892

    PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Not yet reported Brigham and Women's Hospital 6000 participants Est. completion 2029-03-01 36 sites
    Cardiovascular disease Other conditions: Type2Diabetes
    View official trial listing →
  • Recruiting NCT NCT05925959

    Preoperative Weight Loss for Open Abdominal Wall Reconstruction

    Not yet reported Benjamin T. Miller 258 participants Est. completion 2027-06-01 2 sites
    Other conditions: Abdominal Wall Hernia
    View official trial listing →
  • Recruiting NCT NCT06374875

    Fibrosis Lessens After Metabolic Surgery

    Not yet reported The Cleveland Clinic 120 participants Est. completion 2029-12-31 22 sites
    MASLDMASH Other conditions: Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, Obesity
    View official trial listing →
  • Recruiting NCT NCT07042672

    Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

    Haukeland University Hospital 80 participants Est. completion 2028-12-31 1 site
    Other conditions: Binge Eating Disorder Associated With Obesity, Binge Eating Disorder, Eating Disorder Binge, Eating Disorders, GLP-1, CBT, Obesity &Amp; Overweight
    View official trial listing →
  • Completed NCT NCT05390307

    Obesity Treatment to Improve Diabetes

    Not yet reported Dasman Diabetes Institute 60 participants Est. completion 2024-01-01 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Status unknown NCT NCT05492305

    Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health

    King's College London 20 participants Est. completion 2023-08 1 site
    Other conditions: Diabetes Mellitus, Obesity, Mental Health Issue
    View official trial listing →
  • Enrolling by invitation NCT NCT06581120

    GLP_1 RA Ultrasound Study

    Children's Hospital Medical Center, Cincinnati 100 participants Est. completion 2026-07 1 site
    Other conditions: Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07188545

    Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)

    Ohio State University 23280000 participants Est. completion 2029-06-30 1 site
    Metabolic syndrome
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.